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Introduction
 Breast cancer is the most common malignancies among 
women worldwide, with an increase in incidence from 
10.9 to approximately 20 million new cases per year by 
the year 2020 (Parkin et al., 2001; Lehmann et al., 2011). 
Breast cancer also ranks first among cancers diagnosed 
in Iranian women (Mousavi et al., 2009; Kolahdoozan et 
al., 2010; Movahedi et al., 2012). 
 Positive family history is a confirmed risk factor for 
breast cancer, as the risk to first-degree relatives of a case 
is almost 2 times the population risk (Collaborative group, 
2001). Majority of the familial risk associated with breast 
cancer have a genetic origin (Ponder, 2001; Benusiglio et 
al., 2005).
 Highly penetrate germline mutations in BRCA1 and 
BRCA2 account for the large majority of autosomal 
dominant familial breast-ovarian cancer (Bennett, 1999; 
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Abstract
 Background: The EMSY gene encodes a BRCA2-binding partner protein that represses the DNA repair 
function of BRCA2 in non-hereditary breast cancer. Although amplification of EMSY gene has been proposed to 
have prognostic value in breast cancer, no data have been available concerning EMSY tissue expression patterns 
and its associations with clinicopathological features. Materials and Methods: In the current study, we examined 
the expression and localization pattern of EMSY protein by immunohistochemistry and assessed its prognostic 
value in a well-characterized series of 116 unselected breast carcinomas with a mean follow up of 47 months 
using tissue microarray technique. Results: Immunohistochemical expression of EMSY protein was detected in 
76% of primary breast tumors, localized in nuclear (18%), cytoplasmic (35%) or both cytoplasmic and nuclear 
sites (23%). Univariate analysis revealed a significant positive association between EMSY expression and lymph 
node metastasis (p value=0.045) and larger tumor size (p value=0.027), as well as a non-significant relation with 
increased risk of recurrence (p value=0.088), whereas no association with patients’ survival (log rank test, p 
value=0.482), tumor grade or type was observed. Conclusions: Herein, we demonstrated for the first time the 
immunostaining pattern of EMSY protein in breast tumors. Our data imply that EMSY protein may have impact 
on clinicipathological parameters and could be considered as a potential target for breast cancer treatment. 
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Bane et al., 2011; Mutch et al., 2013). The estimated 
lifetime risk of breast cancer with a BRCA1 or BRCA2 
mutation can be as high as 65%-74 % (Mutch et al., 2013). 
The prevalence of BRCA mutations varies by population: 
0.2 to 0.3 percent in general populations, 3 percent in 
women with breast cancer, 6 percent in women with breast 
cancer onset before age 40 years, 10 percent in women 
with ovarian cancer, and 20 percent in high-risk families 
(Nelson et al., 2013).
 BRCA genes are implicated in RAD 51 and mediate 
recombinational repair of double stranded DNA breaks, 
chromatin remodeling and regulation of transcription 
(Venkitaraman, 2002; Hughes-Davies et al., 2003). 
Whereas, familiar breast cancer is the cause of 5% of all 
breast cancers, sporadic breast cancers account for more 
than 95% of all breast cancer types. Mutations of BRCA1/2 
genes are frequently observed in hereditary breast and 
ovarian cancers, additionally altered expressions of 
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BRCA1/2 proteins potentiate sporadic forms of breast 
cancer (Paul and Paul, 2014).
 Nevertheless, the role of BRCA1 and BRCA2 genes 
in sporadic breast cancer remains unexplained, since 
somatic mutations in both genes are uncommon (Gayther 
et al., 1998). Silencing of BRCA1 allele through promoter 
methylation occurs in somatic breast cancer (Dobrovic 
and Simpfendorfer, 1997), whereas this mechanism of 
transcriptional suppression could not explain the absence 
of somatic BRCA2 mutations in sporadic cancers (Collins 
et al., 1997).
 The discovery of EMSY in 2003 by Hughes-Davies 
et al, links the important role of BRCA2 to sporadic 
breast-ovarian cancer. EMSY, binds to exon 3 of BRCA2 
and suppresses the transactivity of BRCA2. EMSY is 
over expressed in sporadic breast and ovarian cancers, 
suggesting that its overexpression may mimic the effects 
of BRCA2 inactivation, functionally equivalent to loss 
of BRCA genes in familial cases (Hughes-Davies et al., 
2003). In addition, since EMSY is a BRCA-2 partner 
which modulates BRCA-2 function, it can be concluded 
that EMSY participates in breast cancer development 
(Livingston, 2004; Yao and Polyak, 2004).
 EMSY localizes to the sites of DNA repair following 
DNA damage and maps to chromosome 11q13.5, 100 kb 
centromeric to the GARP gene, a locus that is known to be 
involved in a number of cancers including breast, ovarian 
and prostate cancers (Nurminen et al., 2011). Recently 
Nurminen et al showed that 11q13.5 contributes to prostate 
cancer predisposition with complex genetic structure and 
is associated with prostate cancer death (Nurminen et al., 
2013).
 Amplification of EMSY has been reported in 13% 
of sporadic breast cancer, 17% of high grade ovarian 
cancer and 13 % of sporadic pancreatic adenocarcinomas 
(Schuuring, 1995; Hughes-Davies et al., 2003; Rodriguez 
et al., 2004; Brown et al., 2006; van Hattem et al., 2008).
 In a recent study conducted by Wilkerson et al, 
amplification of EMSY was found in 10 cancer cell lines 
from different anatomical origins including breast, ovary, 
pancreas, oesophagus, lung and the oral cavity (Wilkerson 
et al., 2011).
 EMSY amplification has been associated with worse 
survival, particularly in node-negative breast cancers, 
suggesting that EMSY may be an indicative of poor 
outcome of the disease (Hughes-Davies et al., 2003). 
Therefore, EMSY could be a strong candidate oncogene 
within 11q13.5 region (Rodriguez et al., 2004). 
 Based on the absence of any data in the literature 
concerning immunohistochemical analysis of EMSY 
protein expression in tumor tissues, in this study we aimed 
for the first time to investigate the expression of this 
protein in an unselected series of breast carcinomas using 
tissue microarray technique. In addition, correlation of 
EMSY expression with patients and tumor characteristics 
was assessed.
Materials and Methods
Patients and tumor characteristics 
 A total of 126 breast tissues from unselected series 
(either familial or sporadic) of female patients with 
primary breast cancer diagnosed between 1996 and 2010 
were included in tissue microarrays. Of this, 10 specimens 
were excluded from the study due to technical problems 
in tissue processing or lack of possible tumor cells within 
the core, leaving a total of 116 cases for final evaluation.
 This collection comprises female patients ranging 
from 30 to 79 years of age (mean=52 years) with a long-
term follow-up of 2-180 months (mean=47 months). The 
samples were obtained from Cancer Research Centre; 
Shohada Hospital affiliated to Shahid Beheshti University 
of Medical Sciences, Tehran, Iran. 
 The study of prognostic markers in breast tumors was 
evaluated based on the REMARK criteria (McShane et 
al., 2005). 
 Patient characteristics including age, menopausal 
status and family history of breast cancer were procured 
and information on absence or presence of recurrence, and 
survival was also retrieved from a retrospective database. 
Tumor characteristics, including histological grade, 
tumor type (Bloom and Richardson, 1957), tumor size, 
lymph node involvement were collected and recorded in 
a database (Table 1). 
 The tumor grading of all breast cancers were assessed 
based on Bloom Richardsons system (Bloom and 
Richardson, 1957) by a team of pathologists including 
two fixed pathologists over these years.
 Information on laboratory tests including Her2, 
Estrogen Receptor (ER), and Progesterone Receptor 
(PR) were also assessed routinely and included in 
database (Table 2). ER and PR status was assessed by 
immunohistochemistry (IHC) technique and a cut-off of 
10% for nuclear staining was used to determine positivity. 
The assessment of the HER2 status was done by IHC 
and the results interpreted as positive (3+), negative (0-
1+), or equivocal (2+). Only cases with a diffuse intense 
membrane staining pattern in the tumor (scored as 3+) 
were considered HER2 positive by IHC.
 All patients received surgery (either modified radical 
mastectomy or breast-conserving surgery) which followed 
by radiotherapy (90%). Patients with lymph node 
metastasis even <3 had radiation therapy with at least 2 
specific fields and patients with 4 or >4 involved lymph 
nodes received at least 3 specific fields radiation therapy 
plus systemic therapy.
 One hundred and seven (93%) cases received 
chemotherapy, at least 5 cases received neoadjuvant 
chemotherapy (that for these cases tumor size was not a 
significant data due to chemotherapy efficacy), and fewer 
patients were given hormone therapy (either tamoxifen 
or aromatase inhibitors) if ER were positive (Table 2). 
This study was approved by Iran University of Medical 
Sciences (IUMS) Research Ethics Committee. 
Tissue microarray (TMA) preparation
 Breast cancer tissue microarrays were prepared as 
described previously (Kononen et al., 1998; Mehrazma 
et al., 2012; Sotoudeh et al., 2012; Mohsenzadegan et al., 
2013). All cases were reviewed and the tumor area was 
marked on their H&E stained slides. Tissue arrays were 
then constructed by placing 0.6 mm diameter samples 
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from 50 different tumor samples per single block, with 1 
mm spacing separating each specimen. The TMA blocks 
were constructed in three copies, each containing one 
sample from a different region of the tumor using tissue-
arraying instrument (Minicore; ALPHELYS, Plaisir, 
France). 
Immunohistochemistry 
 Immunohistochemical detection of EMSY was 
performed on TMA slides (Superfrost plus, Thermo 
Scientific, Germany) using a standard chain polymer-
conjugated (Envision) technique as described previously 
(Madjd et al., 2011; Madjd et al., 2012; Taeb et al., 2014) 
applying specific Rabbit polyclonal antibody (ab 4580, 
abcam, Cambridge, UK). After deparaffinization in 
xylene and rehydration through graded alcohol, slides 
were immersed in methanol/hydrogen peroxide for 10 
min to block endogenous peroxidase activity. Antigen 
was retrieved by autoclaving tissue sections for 10 
minutes in sodium citrate buffer (pH 6.0). The sections 
were then incubated with primary antibody with optimal 
dilution of 1:200 for 1hour at room temperature. After 
washing, the sections were incubated with anti-rabbit/anti-
mouse Envision (Dako, Denmark) secondary antibody 
for 30 minutes. Color was developed with addition 
of 3, 3’-diaminobenzidine (DAB, Dako) to achieve 
visualization of the antigen. In the final step, sections 
were lightly counterstained with haematoxylin (Dako), 
dehydrated in alcohol, cleared in xylene and mounted for 
examination. The omission of primary antibody and its 
replacement with TBS (Tris Buffered Saline) was used as 
negative reagent control.
Evaluation of immunostaining
 The immunostained tissue arrays were evaluated using 
a semi-quantitative scoring system by one observer (ZM) 
in a coded manner without previous knowledge of clinical 
and pathological parameters of patients on two separate 
occasions. In difficult cases, the scoring was confirmed 
by 2 observers and a consensus was achieved between the 
scorings. 
 Initially, the slides were scanned at 10x magnification 
to obtain a general impression of the overall distribution of 
the tumor cells and the positive cores were then assessed 
for localization and semi-quantitatively for expression 
level at higher magnifications and the final scores were 
given. The intensity of the staining was scored on a 
scale as 0 (absent), 1 (weak), 2 (moderate) or 3 (strong). 
The pattern of expression was categorized as nuclear, 
cytoplasmic, or combined nuclear and cytoplasmic 
staining. 
Statistical analysis
 Statistical analysis of data was performed using SPSS 
20 statistical software (SPSS Inc, Chicago, IL). The 
significance of associations between EMSY expression and 
clinicopathologic variables were analyzed using Pearson’s 
χ2 and Pearson’s R tests. 
 Survival rates were examined by the Kaplan-Meier 
method for analysis of censored data. The statistical 
significance of differences between the survival rates of 
groups with different EMSY expression was analyzed 




 At the time of diagnosis, patients’ age ranged from 30 
to 79 years (mean, 52 years). Twenty (17%) cases were 
younger than 40 years old, while 96 (83%) ones were over 
40. Sixty five (56%) patients were in premenopausal, and 
51(44%) were in postmenopausal status. The information 
on family history of breast cancer in this series of 
patients was also recorded. Ninety four (81%) patients 
had no history of breast cancer in their first relatives and 
considered as sporadic breast carcinomas, whereas 22 
cases (19%) had history of breast cancer in one of their 
first relatives.
 Of the 116 tumors, 21 (18%) cases were grade 1, 49 
(42%) cases were grade 2, and 46 (40%) were grade 3. 
The majority of cases were diagnosed as invasive ductal 
carcinoma (IDC) comprising 82% of all cases. Tumor size 
ranged from 1 to 12 cm (mean: 3.8 cm) and categorized in 
three main groups based on TNM classification of breast 
cancers: group 1 tumors were 2.0 cm or less in largest 
dimension comprising 27% (31) of cases. Group 2 tumors 
were 2 to 5 cm including 54% (63) cases and group 3 
tumors were larger than 5.0 cm and included 19% (22) 
of the tumors. 
 At the time of the primary diagnosis, 58 (50%) cases 
Table 1. Correlation of EMSY Expression in Invasive 
Breast Carcinomas with Clinicopathological 
Parameters (Pearson’s χ2)
Tumor and patients No. (%) EMSY expression
characteristics  (p-value)
Age (years, mean= 52)  
 <40  20 (17) 0.26
 >40 96 (83) 
Menopausal status   
 Pre-menopausal 65 (56) 0.33
 Post-menopausal 51 (44) 
Family history  
 No  94 (81) 0.14
 Yes 22 (19) 
Histological Grade  
 Grade 1 21 (18) 0.48
 Grade 2 49 (42) 
 Grade 3 46 (40) 
Tumor size (cm)  
 <2 31 (27) 0.02
 2-5  63 (54) 
 >5 22 (19) 
Lymph node ( LN) status  0.03
 LN negative  59 (51) 
 LN positive 57 (49) 
Tumor type  
 Invasive ductal carcinoma  95 (82) 0.39
 Other tumor types* 21 (18) 
Recurrence  
 Absent 84 (72) 0.08
 Present 32 (28) 
Patients status  
 Alive 90 (78) 0.48
 Dead 26 (22) (log rank test)
*Invasive lobular Carcinoma, Medullary Carcinoma, and infiltrative Carcinoma
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were node negative, in 25 (22%) patients 1-3 lymph nodes 
were involved and in 33 (28%) cases more than 3 lymph 
nodes have been metastasized.
 Among all patients, 90 (78%) were still alive, while 26 
(22%) died from breast cancer, and recurrence occurred 
in 32 (28%) cases. Patients and tumor characteristics, and 
their correlation with EMSY expression are summarized 
in Table 1.
Expression of EMSY in breast carcinomas
 Immunohistochemical expression of EMSY within the 
breast tumors was broadly heterogenous with variety of 
intensities. The staining pattern of expression was either 
nuclear, cytoplasmic, or combined pattern in tumor cells. 
EMSY stromal staining was weak and insignificant, and 
therefore, it was not considered in the analysis.
 EMSY expression was found in 88 out of the 116 
(76%) unselected invasive breast carcinomas. Nuclear, 
cytoplasmic and combined pattern of EMSY expression 
were found in 21 (18%), 41 (35%) and 26 (23%) cases, 
respectively, whereas 28 (24%) tumors were completely 
negative for EMSY expression (Table 3, Figure 1). 
EMSY expression in relation with clinicopathological 
features of breast carcinomas
 The association between expression of EMSY and 
prognostic parameters (histological grade, lymph 
node involvement, tumor size, tumor type ), patient 
characteristics (age, menopausal status, and familial 
history) and outcome (overall survival and recurrence) 
was investigated in total of 116 unselected series of 
patients and also separately in sporadic breast carcinomas 
(94/ 116). In univariate analysis of unselected (familial 
or sporadic) breast cancer patients, a significant positive 
correlation was observed between EMSY expression and 
lymph node (LN) metastasis (p=0.045); i.e. the higher 
expression of EMSY was more often found in LN positive 
breast tumors particularly those tumors with more than 
3 metastatic LN. The expression of EMSY protein was 
also significantly correlated with increased tumor size 
(p=0.027), indicating higher level of expression of EMSY 
in tumors with larger than 5 cm diameter. Furthermore, 
a relative positive association (p=0.088) was evident 
between EMSY expression and recurrence of breast cancer.
 To evaluate the potential role of EMSY in sporadic 
breast cancers, the proportion of EMSY expression in 
both sporadic and familial subpopulations was compared. 
Figure 1. Expression of EMSY Protein in Breast tumor.
(A) Nuclear, (B) cytoplasmic (C) combined pattern (cytoplasmic 
and nuclear) and (D) No staining of EMSY was observed in 
invasive breast carcinomas (magnification 5100)
Table 3. The Pattern of Expression of EMSY Protein 
in Breast Carcinomas
Immunostaining  Number (%)
No staining 28 (24%)
Cytoplasmic staining 41 (35%)
Nuclear staining 21 (18%) 
Combined pattern (Cytoplasmic& Nuclear) 26 (23%)
Table 2. Different Types of Treatment and Laboratory 
Tests in Breast Carcinomas
Treatment and laboratory tests Number (%)
Surgery Yes 116 (100)
 No 0
 Chemotherapy 107  ( 93)
 Neoadjuvant Chemotherapy  5     (4)
 No Adjuvant/Neoadjuvant chemotherapy 4     (3)
Radiotherapy
 Yes 105   (90)
 No 11   (10)
Hormone therapy
 Yes 93   (80)
 No 23   (20)
Her2 Positive 49   (42)
 Negative 67   (58)
ER Positive 71   (61)
 Negative 45   (39)
PR Positive 71   (61)
 Negative 45   (39)
Figure 2. EMSY Expression and Overall Survival. Kaplan-Meier curves comparing breast cancer mortality between women 
with EMSY expression (cytoplasmic, nuclear and  combined pattern) and EMSY negative breast cancers. No significant correlation 
was seen between expression of EMSY and breast cancer mortality A) 116 unselected series of breast cancer (log rank, p=0.482). B) 
94 sporadic breast cancer patients, (log rank, p=0.958). 
A
 1: EMSY Negative (n=28)
 2: EMSY expression (n=88)
 P=0.482
B
 1: EMSY Negative (n=20)
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Seventy nine percent (74/94) of sporadic cases expressed 
EMSY, whereas EMSY expression was detected in 64% 
(14/22) of familial breast cancers. Although the proportion 
of EMSY expression in familial cases was relatively lower 
compared to sporadic ones, the difference did not reach 
to statistically significant level. 
 Univariate analysis was also performed on 94 sporadic 
cases to evaluate the association between EMSY expression 
and clinicopathological features. As with unselected series 
of breast cancer patients, in subpopulation of sporadic 
breast carcinomas, EMSY expression was significantly 
correlated with LN metastasis (p value =0.038) and larger 
tumor size (p value =0.027). 
 In contrast, no correlation was demonstrated between 
expression of EMSY protein and histological grade, tumor 
type, history of familial breast cancer, menopausal status 
or patient age at time of diagnosis either in total series or 
fraction of sporadic breast carcinomas (Table 1). Similarly 
no significant difference was evident between EMSY 
expression and ER status among total series (p value=0.56) 
and sporadic breast carcinomas (p value=0.31).
Survival analysis in relation to EMSY expression 
 Correlation between the expression of EMSY, and 
overall survival for all breast cancer patients, with a mean 
of 47 months (4 years) follow up period, was assessed. 
Based on Kaplan-Meier analysis, no significant association 
was found between the EMSY expression and patient 
survival (p value=0.482, Figure 2 A).
 Similarly, no significant correlation was seen between 
the expression of EMSY and overall survival of the 94 
sporadic breast cancer patients, (p value=0.958, Figure 2 
B).
 In addition, in spite of various patterns of EMSY 
expression in breast tumors, there was no significant 
difference in the localization of EMSY protein regarding 
survival data.
Discussion
Breast cancer is the most common cancer diagnosed 
in women worldwide (Lehmann et al., 2011). It is also 
reported as the most common malignancy among Iranian 
females (Sadjadi et al., 2005; Mousavi et al., 2009; 
Kolahdoozan et al., 2010; Harirchi et al., 2011). Breast 
cancer, like other tumor types, is developed as a result 
of cumulative genetic and epigenetic changes. Although 
the majority of inherited breast carcinomas caused by 
germline mutations in the BRCA1 and BRCA2 tumor 
suppressor genes (Miki et al., 1994; Wooster and Stratton, 
1995; Hofmann and Schlag, 2000), the involvement of 
these genes in sporadic cancers is still uncertain (Yao and 
Polyak, 2004).Sporadic breast cancers result from a serial 
multi step accumulation of acquired mutations in somatic 
genes, without any germ line mutations (Kenemans et 
al., 2004).
EMSY, a novel BRCA2 binding protein was identified 
as putative oncogene which involves the BRCA2 pathway 
in sporadic tumors (Hughes-Davies, 2003). EMSY can 
interact with BRCA2 and inhibit its function, therefore 
EMSY amplification provides a possible explanation for 
the lack of BRCA2 mutation in sporadic breast cancers 
and emphasizes on the contribution of this protein in breast 
tumorigenesis (Hughes-Davies, 2003).
This study aimed to investigate the expression of 
EMSY protein and its correlation with prognostic value 
and patient outcome, in a well-characterized series of 
breast carcinomas compromising 94 sporadic and 22 
familial cases.
Our immunostaining analysis demonstrated that the 
majority (76%) of breast carcinomas expressed EMSY 
protein either nuclear or cytoplasmic, whereas in some 
cases EMSY localized in both cytoplasm and nuclear 
site. In an elegant work by Hughes-Davies et al. using 
immunofluorescent staining, it was demonstrated that 
EMSY, as with BRCA2, is re-localized to the nucleus in 
response to DNA damage (Hughes-Davies et al., 2003). 
In contrast to this finding, the results of our study clearly 
showed that in addition to nuclear localization, a large 
proportion of breast cancer cells express EMSY in their 
cytoplasm. It is notable that in this research work, wild 
type embryonic fibroblastic cell line was used as a model 
to assess the function of EMSY protein (Hughes-Davies 
et al., 2003). We believe that in cancer cells ectopically 
expressed proteins may have different localization and 
serve distinct function.
The proportion of nuclear staining of EMSY protein 
presented here is accordance with previous fluorescence 
in situ hybridization study reporting that EMSY was 
amplified in 18% (5/28) of breast cancer cell lines and in 
only 13% (70/551) of primary sporadic breast tumors in 
a TMA setting (Hughes-Davies et al., 2003). 
In this study, it was observed that cell lines with 
EMSY genomic amplification had the highest levels of 
EMSY gene expression, as judged by Quantitative RT-
PCR, indicating that amplification of EMSY gene leads 
to increased expression of EMSY (Hughes-Davies et al., 
2003). Despite of comprehensive survey on EMSY gene 
expression in a complete set of breast cancer cell lines, 
the expression of its protein has been reported neither 
in breast cancer cell lines nor in primary breast tumors. 
In this study, we report for the first time the expression 
of EMSY protein in primary breast cancer tissues using 
immunohistochemistry. Expression of EMSY was detected 
in 76% of invasive breast carcinomas investigated, whereas 
Table 4. Correlation of EMSY Expression with 
Lymph node Involvement and Tumor Size of Breast 
Carcinomas (Pearson’s χ2)
 EMSY expression
Tumor Total.  No staining  Cytoplasmic p-value
Features Number  /Nuclear/ 
   combined pattern
  n (%) n (%) 
Tumor size (cm)    
  <2 31 12 (39) 19 (61) 0.02
  2-5 63 13 (21) 50 (79) 
  >5 22 3 (14)  19 (86) 
Lymph node (LN) involvement    
  LN negative 58 19 (33) 39(67) 
  1-3 LN 25 4(16) 21(84) 0.04
  >3 LN 33 5 (15) 28 (85) 
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only 24% of cases were completely negative. Expression 
of EMSY protein was slightly higher in subpopulation of 
sporadic breast carcinomas compared to unselected or 
familial cases, but no significant difference was found. 
This may be due to the limited number of familial cases 
in our series or involvement of other mechanisms in 
suppression of BCRA2 in sporadic breast cancer. 
Univariete analysis revealed a positive association 
between EMSY expression and larger tumor size, also an 
increased incidence of lymph node metastasis; however, 
there was no association between EMSY expression and 
tumor grade or type. This findings are in agreement 
with previous study conducted in 364 primary breast 
tumors using FISH showing that EMSY amplification 
was associated with larger tumor size and lymph node 
metastasis but no association with tumor type or grade was 
indicated (Bane et al., 2011). Although various patterns of 
EMSY expression ( nuclear, cytoplasmic or combined) was 
observed in this series of breast tumors, we did not find any 
significant difference in the localization of EMSY protein 
regarding survival data in spite of this belief that “different 
localization of EMSY” may “serve distinct function”.
A recent report on comparing EMSY copy number 
within breast ductal carcinoma in situ (DCIS) by multiplex 
ligation-dependent probe amplification (MLPA), showed 
that EMSY amplification was more frequent in high-grade 
DCIS than in low/intermediate-grade DCIS, suggesting 
that in high grade DCIS, EMSY may be potential target 
for treatment and/or an predictor of progression (Moelans 
et al., 2010; Moelans et al., 2011). We were unable to 
investigate EMSY expression separately in DCIS due to 
small number of cases.
In a more recent study by Kornegoor et al, the copy 
number changes of 21 breast cancer related genes in 
110 male breast cancers were evaluated using MLPA, 
indicating that in male breast cancer EGFR and CCND1 
were more often gained than in the female breast cancer 
group, whereas EMSY and CPD copy number gain was 
less frequent (Kornegoor et al., 2012).
Our collection included only female breast cancer; 
therefore we were unable to show the differences in the 
level of expression of EMSY protein between female and 
male breast cancers.
Our results also demonstrated that expression of 
EMSY protein was relatively associated with recurrence 
of breast cancers. Similarly, amplification of EMSY was 
correlated with increased risk of relapse particularly in 
grade 1 breast tumors in a study performed by southern 
blotting (Rodriguez et al., 2004).
Furthermore, amplifications of EMSY was observed 
in 7.2% and 9.6% of consecutive and ER+ tamoxifen-
treated patients (Kirkegaard et al., 2008) and EMSY 
amplification was correlated with positive ER status in 
a subset of sporadic breast cancer patients (Rodriguez et 
al., 2004). Nevertheless, no significant association was 
evident between EMSY expression and ER or PR status 
in our series of patients.
EMSY amplification has been reported to be associated 
with a poor patient outcome in some previous studies, 
using stratified patient groups including lymph node-
negative (Hughes-Davies et al., 2003), lymph node-
positive (Rodriguez et al., 2004), or ER-positive breast 
cancers (Kirkegaard et al., 2008), whereas in other studies 
such association have not been demonstrated (Bane et 
al., 2011).
Hughes-Davies et al. showed that in sporadic breast 
cancers, EMSY amplification was associated with worse 
survival, particularly in node-negative breast cancer, 
suggesting that it may be of prognostic value, whereas 
among node-positive patients, no such association was 
found proposing that EMSY amplification alone is not a 
distinctive risk factor in all breast cancer patients (Hughes-
Davies et al., 2003).
In our survival analysis using Kaplan-Meier method, 
there was no association between overall survival and 
EMSY expression (log-rank test p=0.482), even when we 
restricted the analysis to lymph node positive or lymph 
node negative tumors. The clinical significance of these 
findings needs further investigation in larger patient 
groups. 
In conclusion, in the present study, we demonstrated 
for the first time the immunostaining pattern of EMSY 
protein in an unselected series of breast tumors using 
tissue microarray technique.
Collectively, our data imply that EMSY protein 
expression is correlated with increased tumor size, lymph 
node metastasis and relatively higher rate of recurrence. 
Therefore, EMSY may be potential target for breast cancer 
treatment, but further studies with larger size of patients 
are required before such conclusion could be consolidated.
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